ACTG 261--DLV + AZT AND/OR DDI VS AZT AND DDI

ACTG 261--DLV AZT 和/或 DDI VS AZT 和 DDI

• 批准号: 6274485
• 负责人: STEPHEN GLUCKMAN
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-15 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274485
• 关键词: 2'3' dideoxyinosine; AIDS therapy; HIV infections; clinical research; clinical trials; combination therapy; delavirdine; drug screening /evaluation; human subject; human therapy evaluation; outcomes research; zidovudine

The purpose of this study is to determine the safety and efficacy of delavirdine (DLV) in combination with AZT and/or ddI compared to AZT and ddI in HIV+ patients with CD4 counts between 100-500 with no previous antiretrovirals or previous cumulative monotherapy of <= 6 months with either AZT or ddI alone.

本研究的目的是确定 地拉韦啶（DLV）联合AZT和/或ddI与AZT相比， 在CD 4计数在100-500之间且既往无 抗逆转录病毒药物或既往累积单药治疗≤ 6个月， AZT或DDI单药